Evidence map›Paper›PMID 32910919›Full record

ArticleCell host & microbe2020

Snatching the Crown from SARS-CoV-2.

Lynda Coughlan

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell host & microbe, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Lynda CoughlanIcahn School of Medicine at Mount Sinai, Department of Microbiology, New York, NY 10029, USA; University of Maryland Baltimore School of Medicine, Department of Microbiology and Immunology and Center for Vaccine Development and Global Health, Baltimore, MD 21201, USA. Electronic address: lcoughlan@som.umaryland.edu.
University of Maryland, Baltimore · US

Funding

Generation of a polycistronic universal influenza virus vaccine based on rare species adenoviral vectorsR21AI146529 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI COUGHLAN, LYNDA · 2019 to 2020
$466k
Exosome-display as a strategy to enhance the immunogenicity of SARS-CoV-2 vaccines based on adenoviral vectorsR21AI157606 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI COUGHLAN, LYNDA · 2020 to 2020
$425k
NIAID NIH HHS HHSN272201400008CNIAID NIH HHS R21 AI146529NIAID NIH HHS R21 AI157606
6 · The paper itself

Abstract

In this issue of Cell Host & Microbe, three papers describe the pseudotyping of vesicular stomatitis virus (VSV) with the SARS-CoV-2 spike. This VSV-CoV-2-S platform allows virus neutralization assays to be performed at BSL-2 and also has applications as a candidate vectored vaccine to elicit protective immunity against SARS-CoV-2.

Indexed as

Antibodies, NeutralizingCoronavirus InfectionsPandemicsPneumonia, ViralBetacoronavirusCOVID-19HumansPeptidyl-Dipeptidase ASARS-CoV-2Antibodies, NeutralizingPeptidyl-Dipeptidase A

Identifiers

PMID32910919
PMCPMC7480642
OpenAlexW3084072591

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.